Drug Profile

Melatonin - Nobelpharma

Alternative Names: Melatobel; NPC-15

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nobelpharma
Developer Kobe University; Nobelpharma
Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
Mechanism of Action Melatonin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Sleep disorders
Phase II Xeroderma pigmentosum

Most Recent Events

17 Mar 2025 Launched for Sleep disorders (In adolescents, In children) in Japan (PO)
14 Mar 2025 Registered for Sleep disorders (In adolescents, In children) in Japan (PO)
31 Jan 2025 Phase-II clinical trials in Sleep disorders in Japan (PO), prior to January 2025 (Nobelpharma pipeline, April 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com